A Phase 4 interventional study of Pitavastatin and Pravastatin in Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.
Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 4, and was the 11th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:
Eccogene · Sites in Australia
Ages 18–65 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
By country, each count listing its studies:
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2010.
This study's enrollment of 252 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 252 across the 21 interventional studies. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
20 studies in Dyslipidemias by Kowa Company, Ltd.: none open now, none under way, none of them phase 3. Of 18 finished, 13 (72%) have results posted.
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 4, and was the 11th registered.
Kowa Company, Ltd.’s Dyslipidemias studies by the year they started, since 2005.
1 of the studies testing pitavastatin in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pitavastatin in Dyslipidemias, from their registry updates:
Among Kowa Company, Ltd.’s 20 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pitavastatin
Drug: Pravastatin
Pitavastatin 4 mg QD
Also known as: Livalo
Pravastatin 40 mg QD
Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks
Time frame: 12 weeks minus baseline
| Milestone | Pitavastatin 4 mg QD | Pravastatin 40 mg QD |
|---|---|---|
| Started | 126 | 126 |
| Completed | 99 | 91 |
| Not completed | 27 | 35 |
| Withdrew: Lost to follow-up | 5 | 11 |
| Withdrew: Protocol violation | 8 | 7 |
| Withdrew: Withdrawal by subject | 4 | 9 |
| Withdrew: Adverse event | 6 | 6 |
| Withdrew: Sponsor decision | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Other | 2 | 0 |
| mg/dL | Pitavastatin 4 mg QD | Pravastatin 40 mg QD |
|---|---|---|
| Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks | 155.1 ± 25.93 | 154.6 ± 23.91 |
Non-serious events are listed at a 1.6% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4 mg QD | — | 7/126 (5.6%) | 10/126 (7.9%) |
| Pravastatin 40 mg QD | — | 3/126 (2.4%) | 5/126 (4%) |
| Event | Pitavastatin 4 mg QD | Pravastatin 40 mg QD |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/126 | 0/126 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/126 | 1/126 |
| Atrial septal defectCardiac disorders | 1/126 | 0/126 |
| Cerebrovascular accidentNervous system disorders | 0/126 | 1/126 |
| Chest painCardiac disorders | 1/126 | 0/126 |
| DiverticulitisGastrointestinal disorders | 1/126 | 0/126 |
| Enterovesical fistulaGastrointestinal disorders | 1/126 | 0/126 |
| GastroenteritisGastrointestinal disorders | 1/126 | 0/126 |
| Gastroenteritis viralGastrointestinal disorders | 1/126 | 0/126 |
| Herpes dermatitisInfections and infestations | 1/126 | 0/126 |
| Event | Pitavastatin 4 mg QD | Pravastatin 40 mg QD |
|---|---|---|
| NauseaGastrointestinal disorders | 1/126 | 3/126 |
| FatigueGeneral disorders | 2/126 | 1/126 |
| HeadacheGeneral disorders | 2/126 | 1/126 |
| Upper abdominal painGastrointestinal disorders | 2/126 | 0/126 |
| Blood CK increasedBlood and lymphatic system disorders | 2/126 | 0/126 |
| DiarrhoeaGastrointestinal disorders | 2/126 | 0/126 |
| Age, Categorical(Participants) | Pitavastatin 4 mg QD | Pravastatin 40 mg QD | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 126 | 126 | 252 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Pitavastatin 4 mg QD | Pravastatin 40 mg QD | Total |
|---|---|---|---|
| Female | 20 | 15 | 35 |
| Male | 106 | 111 | 217 |
| Region of Enrollment(participants) | Pitavastatin 4 mg QD | Pravastatin 40 mg QD | Total |
|---|---|---|---|
| United States | 126 | 126 | 252 |
The record gives a start of Dec 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Kowa Research Institute, Inc. →